康龙化成
PHARMARON

Integrated Drug Discovery Services

Pharmaron's integrated drug discovery services team leads projects from hit identification through candidate selection and beyond. We combine world-class scientific and project leadership with global resources and expertise to offer integrated end-to-end support for discovery and development of new therapeutics.

Computational Sciences

- Cheminformatics
- Structure-based Drug Design
- Target Analysis
- ML/AI-driven Modeling

Chemistry

- Medicinal & Synthetic Chemistry
- Scaffold Design
- Libraries
- API Route Design
- API Scale Up

Biosciences

- Protein Production
- Crystallization & Structural Biology
- *in vitro* Biology
- *in vivo* Pharmacology
- Biomarkers

Hit Identification

- e.g., HTS, DEL, Fragment-based or Phenotypic Screening

Target Science

- Target Identification
- Target Validation
- Cell Line Engineering

Integrated Drug Discovery

DMPK & Safety

- ADME
- PK/PD
- Drug Safety Assessment
- Human Projections
- Modeling and Simulations

IND Application

IND Enabling

- GLP Safety Assessment
- API Process Chemistry; GMP Synthesis
- Formulation Development and GMP Preparation
- DMPK and Pharmacology
- Regulatory Affairs

Preclinical Candidate Nomination

Co-piloting or independent delivery, FTE, risk-sharing or milestone-based, Pharmaron's integrated services team has a solution for you.

康龙化成
PHARMARON

Our integrated approach provides scientific excellence combined with efficient delivery.

Approach

The collective expertise of our seasoned drug hunting team, each member with multi-year industry experience and a proven track record, provides **strategy, decision-making** and **project coordination** to transform ideas into high-quality drug candidates.

Expertise

Our integrated drug discovery team has operated over many years, across **therapeutic areas**, **target types** and **modalities**, successfully advancing projects from hit-finding through preclinical candidate selection into the clinic.

Therapeutic Areas

- Cancer
- Metabolic diseases
- Cardiovascular diseases
- Inflammation/pain
- Immunologic diseases
- Neurologic diseases
- Rare diseases

Target Types

- Enzymes
- GPCRs
- Transporters
- Chaperones
- Nuclear receptors
- Transcription factors
- Phenotypic
- Ion channels

Modalities

- Orthosteric, allosteric binders
- Covalent binders
- Protein degraders
- Molecular glues
- Small and large molecules
- ADCs

Why work with Pharmaron?

- Leverage the expertise of an experienced, multi-disciplinary scientific leadership team working in close collaboration with your team
- Benefit from nimble and flexible resource allocation, utilizing Pharmaron's comprehensive capabilities, instrumentation, and human resources across the UK, US, and China.
- Tap into scientific expertise across all relevant research fields and utilize state-of-the-art technology to facilitate efficient Design-Make-Test-Analyze cycles.
- Eliminate the coordination between different service providers and transform Pharmaron's industry leading turnaround times into accelerated drug discovery

bd@pharmaron.com
www.pharmaron.com

康龙化成
PHARMARON

Selected publications highlighting our scientists' expertise.

Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator

Journal of Medicinal Chemistry. 2024.



Discovery of a novel series of selective macrocyclic PKCTheta inhibitors

Bioorganic & Medicinal Chemistry Letters. 2024.

A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors

Molecular Cancer Therapeutics. 2024.



Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models

Xenobiotica. 2022.



Talk to our scientists about your drug discovery program today.

康龙化成
PHARMARON

bd@pharmaron.com
www.pharmaron.com

Laboratory Services

Chemistry, Manufacturing and Control

Clinical Development

Biologics & CGT